Newsfeeds - Spark Newswire

1 minute read

Roche’s Alzheimer’s Antibody Reduces Associated Biomarkers In Subset Of AD Patients, Study Shows

Today, 1:55 PM

Experimental anti-amyloid antibodies from Eli Lilly & Co (NYSE:LLY) and Roche Holding AG’s (OTC:RHHBY) failed to improve symptoms of Alzheimer’s disease (AD)…

LLY

1 minute read

FDA
News

Eli Lilly Canada Reports Health Canada Issued Notice Of Compliance With Conditions For Retevmo

By Benzinga Newsdesk

Today, 1:55 PM

-Reuters

LLY

1 minute read

Biden Administration Devotes Over $3.2B For Development Of Oral Antiviral Therapies For COVID-19: CNBC

By Vandana Singh

Today, 1:55 PM

Officials on Thursday announced that the Biden Administration plans to invest more than $3.2 billion in developing antiviral medicines to…

BNTX

1 minute read

Eli Lilly To Test Injectable Migraine Med Against Biohaven’s Oral Nurtec In Head-To-Head Study

By Vandana Singh

Today, 1:55 PM

Eli Lilly And Co (NYSE:LLY) will conduct a head-to-head study comparing once-monthly injectable Emgality (galcanezumab-gnlm) with Biohaven Pharmaceutical Holding Co Ltd’s (NYSE:BHVN) Nurtec…

BHVN

1 minute read

JP Morgan Maintains Overweight on Eli Lilly, Raises Price Target to $260

By Benzinga Newsdesk

Today, 1:55 PM

JP Morgan analyst Chris Schott maintains Eli Lilly (NYSE:LLY) with a Overweight and raises the price target from $240 to $260.

LLY

3 minute read

Lilly Announces Head-To-Head Study Comparing Once-Monthly Emgality With Every-Other-Day Nurtec ODT For Preventive Treatment Of Migraine

By Bill Haddad

Today, 1:55 PM

To advance the science of migraine treatment and aid the understanding of calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) compared to oral CGRP receptor antagonists in the prevention of migraine, Eli

LLY

1 minute read

Goldman Sachs Maintains Buy on Eli Lilly, Raises Price Target to $270

By Benzinga Newsdesk

Today, 1:55 PM

Goldman Sachs analyst Terence Flynn maintains Eli Lilly (NYSE:LLY) with a Buy and raises the price target from $252 to $270.

LLY

3 minute read

Media

The Latest Barron’s Picks And Pans: DocuSign, UPS, Taiwan Semiconductor And More

By Nelson Hem

Today, 1:55 PM

The cover story in this weekend's Barron's examines how teenage traders are shaking up the market. Other featured articles discuss which drugmakers benefit from a new market, why it is time to buy momentum stocks and how to safely hunt for yield.

AAPL